Pharvaris (NASDAQ:PHVS) Rating Lowered to “Sell” at Wall Street Zen

Pharvaris (NASDAQ:PHVS) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

PHVS has been the subject of a number of other reports. Morgan Stanley increased their price target on Pharvaris from $41.00 to $46.00 and gave the company an “overweight” rating in a research note on Thursday, June 25th. Citigroup restated a “buy” rating on shares of Pharvaris in a research report on Wednesday, April 15th. UBS Group set a $74.00 target price on Pharvaris in a report on Wednesday, May 13th. Wedbush increased their target price on Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a research report on Tuesday, April 7th. Finally, Royal Bank Of Canada cut their price target on Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a research note on Monday, April 6th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Pharvaris has an average rating of “Moderate Buy” and an average price target of $50.08.

Pharvaris Trading Up 3.8%

Shares of Pharvaris stock opened at $34.94 on Friday. The firm’s 50 day moving average is $32.16 and its 200 day moving average is $28.99. The firm has a market capitalization of $2.29 billion, a PE ratio of -10.99 and a beta of -2.34. Pharvaris has a 1 year low of $19.12 and a 1 year high of $36.60.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.12. As a group, research analysts anticipate that Pharvaris will post -3.2 earnings per share for the current year.

Insider Activity at Pharvaris

In related news, insider Peng Lu sold 15,000 shares of the firm’s stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $30.24, for a total transaction of $453,600.00. Following the completion of the transaction, the insider directly owned 66,083 shares of the company’s stock, valued at $1,998,349.92. This trade represents a 18.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Wim Souverijns sold 10,000 shares of the firm’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $29.92, for a total value of $299,200.00. Following the transaction, the insider directly owned 45,111 shares of the company’s stock, valued at approximately $1,349,721.12. This represents a 18.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 303,356 shares of company stock valued at $9,746,065 in the last quarter. Insiders own 11.84% of the company’s stock.

Institutional Investors Weigh In On Pharvaris

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Tudor Investment Corp ET AL bought a new position in shares of Pharvaris during the third quarter worth about $1,943,000. PSP Research LLC bought a new stake in Pharvaris in the fourth quarter valued at approximately $569,000. JPMorgan Chase & Co. boosted its holdings in Pharvaris by 710.4% in the third quarter. JPMorgan Chase & Co. now owns 27,085 shares of the company’s stock valued at $676,000 after acquiring an additional 23,743 shares during the last quarter. Seven Fleet Capital Management LP bought a new stake in Pharvaris in the fourth quarter valued at approximately $1,536,000. Finally, Eversept Partners LP acquired a new stake in Pharvaris during the 4th quarter valued at approximately $12,187,000.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.